Cystic Fibrosis Therapeutics Market Poised for Remarkable Growth: Anticipated 14.40% CAGR (2022-2028) Driven by Escalating CF Prevalence, Expanding Clinical Pipeline, and Increasing Treatment Rates
28 Nov, 2023

According to Renub Research's latest report, "Cystic Fibrosis Therapeutics Market, Size, Share, Global Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Company Analysis," the Cystic Fibrosis Therapeutics Market is predicted to reach US$ 24.35 Billion by 2028.

Cystic Fibrosis is a genetic disorder characterized by life-limiting effects on the lungs and digestive system. It results from a genetic mutation in the CFTR gene. This mutation follows an autosomal recessive pattern, meaning it is not on the sex chromosome. Symptoms manifest solely when both alleles of the gene undergo mutation. This form of autosomal recessive inheritance underscores that individuals must receive two altered copies of the gene—one from each parent—for the disorder to become evident. The severity of the damage to the lungs and digestive system underscores the impact of this genetic condition on affected individuals. CFTR protein is an ion channel and belongs to the ABC transporter class. Its gene is found on chromosome 7 in the long arm.

The number of individuals diagnosed with cystic Fibrosis has been on the rise over the past decade, according to the CF Foundation. In the US alone, 40,000 children and adults are living with CF, while an estimated 105,000 people across 94 countries have been diagnosed with the condition. As the number of patients increases yearly, the demand for effective and efficient CF treatments also surges. Some commercially approved drug classes include CFTR modulators, bronchodilator drugs, mucolytic drugs, anti-infective antibiotics (oral, inhaled, or parental feeding formulae), anti-inflammatory drugs, and pancreatic enzyme supplements.

Inhale category dominates the market share of the global Cystic Fibrosis Therapeutics Market.

Oral drugs dominate the global cystic fibrosis Therapeutics Market, primarily due to the convenience associated with oral administration. Nevertheless, the landscape may shift by introducing new drug formulations that allow easy administration without invasive procedures, potentially diminishing the market share of oral formulations in favor of alternatives like inhalation drugs.

The increasing adoption of non-invasive medical interventions, such as injections and inhalations, is expected to experience the highest Compound Annual Growth Rate. This trend is influenced by the preference of medical practitioners for these options. Furthermore, inhaled drugs present an effective solution for high-risk patient groups, particularly cystic fibrosis patients grappling with respiratory disorders.

Report Details:

The medication treatment method will capture more than one-third of the market share.

The medication treatment method sector in the cystic fibrosis therapeutics market holds the maximum share. Medications such as aerosolized antibiotics, bronchodilators, mucus thinner, and CFTR modulators, among others, help to reduce lung flare-ups and respiratory symptoms and enhance patients' short-term quality of life. Such factors increase the demand for medications. Other growing factors in the CF treatment industry, such as rising demand and awareness about advanced medications, help expand the industry. New product launches and regulatory approvals for commercializing cystic fibrosis therapeutics will further impact the industry's progression.

The pulmonary Function Test Type segment has a dominating market share.

The surge in occurrences of lung cancer and other chronic pulmonary diseases, coupled with a rising mortality rate, constitutes the primary driving force behind the growth of the pulmonary function testing market. The escalating need for minimally invasive tests to formulate precise treatment strategies for lung ailments, coupled with the widespread consumption of tobacco, predominantly in the form of cigarettes, contributes significantly to the market's expansion. The adoption of pulmonary function testing is propelled by its role in assessing lung health and ensuring the respiratory tract's freedom from infections. These factors collectively accelerate the growth of the pulmonary function testing market.

Increasing hospital visits to treat cystic Fibrosis will fuel the overall market revenue.

The hospital segment is anticipated to secure nearly half of the market share in cystic fibrosis therapeutics in the upcoming year. This dominance is attributed to the increasing incidence of cystic fibrosis, necessitating accurate diagnoses and ongoing treatments overseen by medical professionals. As a result, there is a heightened frequency of hospital patient visits, driving growth within this segment. Moreover, hospital pharmacies contribute significantly to revenue generation due to the common practice of individuals affected by cystic fibrosis seeking medical prescriptions and appointments from nearby hospitals.

CFTR Modulators Drug Class will gain the maximum revenue in upcoming years

The approval of the first CF transmembrane conductance regulator (CFTR) modulator has changed the face of cystic Fibrosis in the era of precision medicine. The encouraging response of CFTR modulators in the market has led to further research and development activities. Several promising compounds are being evaluated, which can be proven to be alternatives to VX-770 to overcome gating mutations. Vertex Pharmaceutical is conducting a clinical trial on VX-561 (also called deutivacaftor), an analog of VX-770, in which one of the tert-butyl groups was replaced by a per-deuterated one.

North American region is forecasted to grow significantly during the forecast years.

By the projected year, North America is poised to claim more than half of the revenue share in the cystic fibrosis therapeutics market. This dominance is fueled by the escalating incidence of cystic fibrosis and the abundance of treatment options available in the region. The industry's revenue is also boosted by increasing government initiatives, including augmented funding for innovative research and development projects focused on cystic fibrosis drugs. Notably, initiatives like the North American Cystic Fibrosis Conference (NACFC) provide a platform for cystic fibrosis specialists to exchange insights and advancements in therapeutic research and development. Furthermore, factors such as the presence of key market players, a robust healthcare infrastructure, and favorable reimbursement policies will contribute to the sustained demand in the North American market throughout the forecast period.

Key Player

Prominent Global Cystic Fibrosis Therapeutics Market players include Vertex Pharmaceuticals, Abbvie Inc., Novartis Ag, Gilead Sciences, Viatris INC, Pfizer, and AstraZeneca. These key players consistently engage in product innovation, technological advancements, and strategic initiatives like agreements, mergers, and acquisitions to establish a strong presence and influence in the market share.

Market Summary:

Route of Administration – Cystic Fibrosis Therapeutics Market Analysis have been Covered from 2 Viewpoints – (Oral and Inhale)
Treatment – Cystic Fibrosis Therapeutics Market Analysis have been Covered from 3 Viewpoints – (Medication, Devices and Other Treatment)
Test Type – Cystic Fibrosis Therapeutics Market Analysis have been Covered from 5 Viewpoints – (Plumonary Function, Sweat Calories, IRT Test, Faceal Tests and Genetic Tests)
Drug Class – Cystic Fibrosis Therapeutics Market Analysis have been Covered from 4 Viewpoints – (Pancreatic Enzyme Supplements, Mucolytics, Bronchodilators and CFTR Modulators)
Region – Cystic Fibrosis Therapeutics Market Analysis have been Covered from 5 Viewpoints – (North America, Europe, Asia Pacific, Latin America and Middle East & Africa)
All companies have been covered from 3 viewpoints: (Overviews, Recent Developments and Revenues)
Company Covered – Vertex Pharmaceuticals, Abbvie Inc., Novartis Ag, Gilead Sciences, Viatris INC, Pfizer and Astrazeneca

About Us

Renub Research is a Market Research and Consulting Company. We have more than 14 years of experience especially in international Business-to-Business Researches, Surveys, and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. Our clients rely on our market analysis and data to make informed knowledgeable decisions. Our pertinent analysis helps consultants, bankers and executives to make informed and correct decisions.

Contact Us
Renub Research
Phone: +1-478-202-3244 (USA) | +91-120-421-9822 (IND)
Email: info@renub.com
Web: https://www.renub.com
Follow on Linkedin: https://www.linkedin.com/company/renub-research